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Background: Cone and cone-rod dystrophies are clinically and genetically heterogeneous inherited retinal disorders
with predominant cone impairment. They should be distinguished from the more common group of rod-cone
dystrophies (retinitis pigmentosa) due to their more severe visual prognosis with early central vision loss. The
purpose of our study was to document mutation spectrum of a large French cohort of cone and cone-rod
dystrophies.
Methods: We applied Next-Generation Sequencing targeting a panel of 123 genes implicated in retinal diseases
to 96 patients. A systematic filtering approach was used to identify likely disease causing variants, subsequently
confirmed by Sanger sequencing and co-segregation analysis when possible.
Results: Overall, the likely causative mutations were detected in 62.1 % of cases, revealing 33 known and 35 novel
mutations. This rate was higher for autosomal dominant (100 %) than autosomal recessive cases (53.8 %). Mutations
in ABCA4 and GUCY2D were responsible for 19.2 % and 29.4 % of resolved cases with recessive and dominant
inheritance, respectively. Furthermore, unexpected genotype-phenotype correlations were identified, confirming the
complexity of inherited retinal disorders with phenotypic overlap between cone-rod dystrophies and other retinal
diseases.
Conclusions: In summary, this time-efficient approach allowed mutation detection in the most important cohort of
cone-rod dystrophies investigated so far covering the largest number of genes. Association of known gene defects
with novel phenotypes and mode of inheritance were established.
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Cone and cone-rod dystrophy (CCRD) refer to a hetero-
geneous group of inherited retinal disorders (IRDs),
characterized by predominant cone impairment. They
are the most common cause of hereditary cone dysfunc-
tion, with a prevalence of 1:40000 [1]. Patients typically
complain of progressive central visual loss associated
with photophobia and colour vision abnormalities in
childhood or early adult life. In case of associated rod
system involvement, patients may also experience dim
light vision disturbances and peripheral visual field con-
striction, leading to severe visual loss and complete
blindness in some cases [1]. On fundoscopy, the macular
appearance ranges from normal to bull’s eye maculopa-
thy or more severe macular atrophy with possible pig-
mentary changes in the periphery in case of rod
photoreceptor involvement [2]. Full-field electroretino-
gram (ERG) is the key examination for diagnosis and re-
veals predominant cone dysfunction with rod responses
initially normal or minimally impaired. Advanced stages
are characterized by both cone and rod impairment
making the differential diagnosis with rod-cone dys-
trophy (or Retinitis Pigmentosa, RP) difficult. Progressive
CCRD need to be distinguished from cone dysfunction
syndromes, which are typically stationary, congenital
with normal rod function [3]. However, these two en-
tities have some phenotypic overlaps with difficulties for
differential diagnosis when the congenital onset is not
clearly documented. In addition CCRD often presents as
an isolated disease, but can also be part of a syndrome
as in Bardet-Biedl, Jalili syndrome or Spinocerebellar
ataxia 7 [1, 5–7].
The genetic basis of CCRD is highly heterogeneous.
Inheritance of CCRD can be either autosomal recessive
(ar), autosomal dominant (ad) or X-linked (xl). Simplex
CCRD are also frequent for which inheritance pattern is
difficult to determine. A recent review estimated that ar
(including isolated cases), ad and xl inheritance were
found in 77 %, 22 %, and 1 % of CCRD, respectively [8].
To date, mutations in 30 genes have been implicated in
CCRD (https://sph.uth.edu/retnet/ March 2015). Muta-
tions in ABCA4 (ATP-binding cassette, sub-family A,
member 4) [8, 9], GUCY2D (Guanylate Cyclase 2D) [10,
11] and RPGR (Retinitis Pigmentosa GTPase regulator)
[12, 13] are major causes of ar, ad, and xl CCRD respect-
ively. Novel gene defects still need to be identified since
recent comprehensive studies genetically resolved less
than 25 % of ar CCRD [2, 8]. Furthermore, clinical and
genetic overlaps exist between CCRD and other IRDs.
Distinct mutations in a same gene can cause distinct
phenotypes, thereby leading to new phenotype-genotype
correlations. For example, mutations in ABCA4, CRX,
CERKL, PROM1, SEMA4A, GUCY2D can cause either
CCRD, but also RP or Leber congenital amaurosis(LCA). In this context, Next Generation Sequencing
(NGS) targeting not only genes known to underlie
CCRD but also more comprehensively other genes mu-
tated in IRDs provides the method of choice, compared
to Sanger sequencing, to encompass clinical and genetic
heterogeneity of this disease group [14]. Targeted NGS
has been successfully applied for investigating IRD: stud-
ies covering from 45 to 254 known genes implicated in
IRDs were able to genetically resolve from 25 % to 57 %
of cases [14–20]. In contrast, only one study so far ap-
plied NGS, targeting 25 genes, to CRD [21]. The pur-
pose of our study was to conduct a more comprehensive
analysis of CCRD by applying a NGS panel covering 123
genes, improved from a previous report [14], to a French
cohort of 96 clinically well characterized patients (95
index patients) who had never been genetically investi-
gated and therefore assess the distribution and preva-
lence of mutations and genes involved in CCRD.
Methods
Clinical diagnosis of CCRD
Ninety-six patients, from 95 unrelated families (2 sib-
lings) with a presumed diagnosis of non-syndromic
CCRD, were included. Inheritance was determined
considering the transmission pattern of the disease
phenotype in the family. Ad transmission was clearly
established for 13 patients (1 of the 2 parents affected,
transmission to offspring, male and female affected with
equal frequency, male-to-male transmission). Ar trans-
mission was strongly suspected when consanguinity was
present in the family or when only one generation was
affected by the disease (39 patients). The remaining 44
patients were isolated CCRD for whom no clear inherit-
ance pattern could be determined (sporadic cases). Con-
sanguinity was present in 31 families. NGS does not
capture the repetitive region ORF15 of RPGR, implicated
in X-linked CCRD, which is a limit of the NGS tech-
nique. To avoid this hurdle, we voluntarily excluded
patients with suspected x-linked transmission, by includ-
ing only women (n = 76), or men with father-son trans-
mission (n = 2) or reported consanguinity (n = 18) in
parents. Thus in theory patients with x-linked transmis-
sion were excluded from this studied population. This
should however be taken with caution since in RP, some
female carriers of mutated x-linked genes can also reveal
a disease phenotype [22]. Each patient underwent full
ophthalmic examination as described earlier [23]. Total
genomic DNA was extracted from peripheral blood
samples according to manufacturer recommendations
(Puregen Kit, Qiagen, Courtabœuf, France). Written
informed consent was obtained from each patient
after explanation of the study and its potential out-
comes. The study protocol adhered to the tenets of
the Declaration of Helsinki and was approved by the
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des Personnes Ile de France V).Molecular genetic analysis using NGS
A custom-made SureSelect oligonucleotide probe library
was previously designed in collaboration with a company
(IntegraGen, Evry, France) to capture the exons of 254
known or candidate genes underlying retinal disorders (Ret-
inal Information Network Database https://sph.uth.edu/
retnet/, Pubmed database http://www.ncbi.nlm.nih.gov/
pubmed/, October 2010) [14]. The panel was subsequently
improved for better coverage and cost efficiency. We first
excluded candidate genes for inherited retinal diseases
present in the initial panel, now that the candidate genes
strategy has been replaced by Whole Exome Sequencing
for unsolved patients after targeted NGS. In addition, we
also chose to exclude genes that are associated with a path-
ognomonic phenotype when mutated that can be directly
screened by Sanger technique for cost efficiency. These in-
clude CNGA3, CNGB3 and PDE6H which are associated
with congenital cone dysfunction syndrome (i.e. achroma-
topsia) that may be associated with mild disease progres-
sion but is distinct from cone dystrophy which is not
congenital [24]. Similarly, KCNV2 and CACNA1F when
mutated lead to distinct electrophysiological phenotypes
(namely the so-called super normal rod ERG and a
Schubert-Bornschein type of ERG respectively) [25, 26].
CNNM4 was also excluded from the list of targeted genes
since mutations in this gene are distinctively associated
with amelogenesis imperfecta as part of Jalili syndrome
[27]. In addition, the implication of three novel genes
C21Orf2 [28], RAB28 [29] and TTLL5 [30] in CCRD were
identified and published after the design of the panel and
consequently were not included in this study. The panel
was therefore reduced from 254 to 123 genes impli-
cated in IRDs including 21 CCRD causative genes
and 102 other IRD genes (https://sph.uth.edu/retnet/,
March 2015, Additional file 1).
Sequence capture, enrichment, and elution were per-
formed according to Agilent’s instruction. Subsequent
genomic alignment (with UCSC hg19 for the reference)
and sequence variation annotations were performed as
previously described [14].Filtering approach
In order to identify disease-causing mutations among
non-pathogenic single nucleotide variants, we selected
exonic non-synonymous variants and splice site variants
(±5 base pair apart from exon). Subsequently, we applied
a systematic filter based on the known pattern of inherit-
ance of the gene defect (heterozygous variant in ad,
compound heterozygous or homozygous in ar) and the
allelic frequency reported in public database (dbSNP,HapMap, 1000 Genome, Exome Variant Server) to be ≤
0.5 % for ar and to be ≤ 0.1 % for ad cases.Pathogenic prediction of variants
Frameshift, nonsense, splicing mutations were considered
as most likely disease causing. For missense mutations,
amino acid conservation was studied across 50 species in
UCSC Genome Browser (http://genome.ucsc.edu/). The
amino acid was considered as « highly conserved » if the
residue did not change. Between 1 and 5 variations (differ-
ent from the mutation and not in primates), it was consid-
ered as «moderately conserved ». Between 5 and 7
variations, it was considered as « weakly conserved ».
Otherwise the amino acid was considered as « not con-
served ». Pathogenicity of missense was also evaluated on
the basis of bioinformatic predictions as Polyphen (Poly-
morphism Phenotyping, http://genetics.bwh.harvard.edu/
pph2/) [31], SIFT (Sorting Intolerant From Tolerant,
http://sift.jcvi.org/www/SIFT_enst_submit.html) [32] and
Mutation Taster [33]. We considered the amino acid ex-
change as pathogenic, when it was predicted to be disease
causing by at least one of the programs.
To identify previously reported pathogenic variants,
literature was systematically reviewed for each selected
variant (The Human Gene Mutation Database (HGMD)
Pro, Leiden Open Variation Database (LOVD), Retina
International, Ensembl, NCBI Pubmed).Sanger sequencing validation and co-segregation analysis
All most likely pathogenic variants were confirmed with
direct PCR and Sanger sequencing. Pair of oligonucleotides
were manually designed at least 50 bp upstream and down-
stream from the mutation for PCR-amplification and
sequencing. Amplicons were enzymatically purified (Exo-
SAP-IT, USB Corporation, Cleveland, Ohio, USA pur-
chased from GE Healthcare, Orsay, France) and sequenced
with a commercially available sequencing mix (BigDye-
Term v1.1 CycleSeq kit, Applied Biosystems, Courtabœuf,
France). The sequenced products were purified on a pre-
soaked Sephadex G-50 (GE Healthcare) 96-well multi-
screen filter plate (Millipore, Molsheim, France), the puri-
fied product analyzed on an automated 48-capillary
sequencer (ABI 3730 Genetic analyzer, Applied Biosys-
tems) and the results interpreted by applying a software
(SeqScape, Applied Biosystems). The nomenclature of each
variant was checked applying Mutalyzer (https://mutaly-
zer.nl/check) to concord with the Human Variation Gen-
ome Society guidelines for mutation nomenclature (http://
www.hgvs.org/mutnomen/).
When blood samples from family members were avail-
able, co-segregation analysis was performed to confirm
association of selected variants with the phenotype.
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analysis for ABCA4
Patients found to carry only one pathogenic variant ABCA4
as well as patients with no pathogenic variant after targeted
NGS analysis were investigated for putative large deletions
by a kit (SALSA MLPA probemix P151-B1/P152-B2
ABCA4,MRC-Holland, Amsterdam, Netherland).
Copy number variations (CNVs) analysis
To detect large deletion or duplication in cases where
targeted NGS did not reveal a disease causing variant or
only one heterozygous variant in recessive cases, we de-
veloped an algorithm to extract CNVs from exome
depth obtained from NGS raw data after genomic align-
ment (BAM files). All depth files from a set of samples
to be analyzed (test set) were compiled and correlated
with files from a depth reference set obtained from the
same sequencing tool with the same NGS strategy.
Validation for comparison was made if the correlation
coefficient was >0.97. Individual depth was then com-
pared to the depth of the reference set for each sample
and each target and a score was generated based on the
presumed number of copies within the targeted region.
Targets with a score ≤ 0.5 (suspected of deletion) or ≥1.5
(suspected of duplication) were selected and subse-
quently confronted to data from the general population
reported in CNV databases (e.g. Database of Genomic
Variants, http://dgv.tcag.ca/dgv/app/about) to exclude
common variants (>0.5 % for recessive cases and >0.1 %
for dominant cases). Putative pathogenic CNVs were
checked by direct Sanger sequencing (MERTK), MLPAFig. 1 Percentage of regions with 25-fold coverage per base for each of th
per gene were 244-fold and 248-fold per base, respectively, with a minima(reagent from MRC-Holland SALSA MLPA probemix
P367-A1 BEST1-PRPH2 kit, for PRPH2) and by qPCR
for FSCN2 exon 1 deletion [34].
Results
NGS capture and coverage
For most of the 21 known CCRD genes of the panel,
100 % of the targeted regions had at least 25-fold coverage
per base beside ABCA4, CDHR1, and GUCY2D which
were at least 99 % covered at 25X whereas PITPM3 was
covered at 97 %, RPGR at 98 % and SEMA4A at 98 %
(Fig. 1). The mean and median coverage per gene were
244-fold and 248-fold per base, respectively, with a min-
imal coverage of 171-fold for RAX2. For some regions,
coverage was low (<25-fold per base) or null in several to
almost all samples, in relation with GC-rich sequences
(IMPDH1 exon 1 (95/96 samples), PEX7 exon 1 (87/96
samples), PITPNM3 exon 1 (35/96 samples), FLVCR1
exon 1 (2/96 samples), RP9 exon 1 (51/96) and CHM exon
5). NGS is therefore not a good method for these particu-
lar regions which were studied by Sanger sequencing for
patients with no pathogenic variants after NGS analysis.
On average 450 Single Nucleotide Variants (SNVs) and
57 insertions/deletions were identified per sample.
Identification of pathogenic mutations
Pathogenic mutations in known CCRD genes As listed in
Table 1, a total of 49 different pathogenic or likely
pathogenic variants were found in 11 known CCRD
genes, including 22 previously reported mutations, 17
novel loss-of-function (deletion, frameshift, nonsense,e 21 known CCRD genes of the panel. The mean and median coverage
l coverage of 171-fold for RAX2
Table 1 Summary of 43 patients carrying pathogenic and likely pathogenic mutations in known CCRD genes
ID Type Consang. Gene NM Allele
State
Exon cDNA Protein Coseg. Conservation Polyphen2 Sift Mutation
taster
References
High confidence
CIC00137 simplex ABCA4 NM_000350.2 Ho 47 c.6394G>A p.(E2132K) + Highly Prd D Dc Novel
CIC00765 Ar + ABCA4 NM_000350.2 Ho 47 c.6445C>T p.(R2149*) + - - - - [80] (rs61750654)
CIC03436 Ar + ABCA4 NM_000350.2 Ho 42 c.5892del p.(G1965Efs*9) Np - - - - a
CIC04412 simplex ABC4A NM_000350.2 Het 34 c.4793C>A p.(A1598D) + Weakly Pd T Dc (rs61750155) [9]
ABCA4 NM_000350.2 Het 28 c.4234C>T p.(Q1412*) + - - - - (rs61750137) [9]
CIC04645 Ar + ABCA4 NM_000350.2 Ho 13 c.1924T>C p.(F642L) Np Moderately B D Dc Novel, but c.1924T>A p.F642I
in [81]
CIC05087 simplex ABCA4 NM_000350.2 Ho IVS
11
c.1554+1G>C r.(spl?) Np Highly - - - Novel
CIC05853 simplex + ABC4A NM_000350.2 Ho 22 c.3259G>A p.E1087K Np Highly Prd D Dc (rs61751398) [82]
CIC05854 Ar + ABC4A NM_000350.2 Ho 35 c.4919G>A p.(R1640Q) + Highly Prd D Dc (rs61751403) [83]
CIC05989 simplex ABC4A NM_000350.2 Het 34 c.4837G>A p.(D1613N) + Not B D Dc Novel
ABC4A NM_000350.2 Het 10 c.1302del p.(Q437Rfs*12) + - - - - Novel
ABCA4 NM_000350.2 Het 38 c.5318C>T p.(A1773V) + Moderately Prd D Dc [84]
CIC06170 simplex ABC4A NM_000350.2 Het 44 c.6089G>A p.(R2030Q) + Highly Prd D Dc [80] (rs61750641)
ABC4A NM_000350.2 Het IVS
24
c.3607+3A>T r.(spl?) + Moderately - - - Novel
ABCA4 NM_000350.2 Het 14 c.2034G>T p.(K678N) + Highly Prd D Dc [85]
CIC06735 Ar + ABC4A NM_000350.2 Ho 42 c.5892del p.(G1965Efs*9) Np - - - - a
CIC06913 Ar + ABCA4 NM_000350.2 Ho 21 c.3056C>T p.(T1019M) + Highly Prd D Dc (rs201855602) [86]
CIC04239 Ar + CDHR1 NM_033100.3 Ho 9 c.838C>T p.(R280*) Np - - - Novel
CIC06568 Ar + CERKL NM_001030311.2 Ho 8 c.1090C>T p.(R364*) Np - - - - Thesis (Sergouniotis P. 2012) b
CIC07299 simplex + PDE6C NM_006204.3 Ho 2 c.542del p.(A181Efs*13) Np - - - - Novel
CIC05218 Ar + PDE6C NM_006204.3 Ho IVS
10
c.1413+3A>T r.(spl?) Np Not - - - Novel
CIC05563 Ad SEMA4A NM_022367.3 Het 4 c.302T>C p.(I101T) + Moderately Prd D Dc Novel (rs149652495)
CIC07563 simplex SEMA4A NM_022367.3 Ho 3 c.241C>T p.(R81*) Np - - - - Novel
CIC00324 Ad GUCY2D NM_000180.3 Het 13 c.2512C>T p.(R838C) + Highly Prd D Dc (rs61750172) [10]
CIC03249 Ad GUCY2D NM_000180.3 Het 13 c.2512C>T p.(R838C) + Highly Prd D Dc (rs61750172) [10]
CIC04347 Ad GUCY2D NM_000180.3 Het 13 c.2512C>T p.(R838C) + Highly Prd D Dc (rs61750172) [10]
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Table 1 Summary of 43 patients carrying pathogenic and likely pathogenic mutations in known CCRD genes (Continued)
CIC04918 Ad GUCY2D NM_000180.3 Het 13 c.2512C>T p.(R838C) Np Highly Prd D Dc (rs61750172) [10]
CIC06757 Ad PRPH2 NM_000322.4 Het 1 c.514C>T p.(R172W) + Moderately Prd D Dc (rs61755792) [87]
CIC03621 Ad PRPH2 NM_000322.4 Het 1 c.1-c581+?del - + - - - - Novel
CIC00535 Ad PROM1 NM_006017.2 Het 10 c.1117C>T p.(R373C) + Not Pd D Dc (rs137853006) [3]
CIC01196 simplex PROM1 NM_006017.2 Ho 12 c.1354dup p.(Y452Lfs*13) + - - - - [71]
CIC07045 simplex PROM1 NM_006017.2 Ho IVS
17
c.1984-1G>T r.(spl?) Np Highly - - - Novel (rs373680665)
CIC06642c Ad PROM1 NM_006017.2 Het 1 c.7dup p.(L3Pfs*28) + - - - - Novel
CIC06698c Ad PROM1 NM_006017.2 Het 1 c.7dup p.(L3Pfs*28) + - - - - Novel
CIC04945 simplex PROM1 NM_006017.2 Het 23 c.2383T>C p.(W795R) + Highly Prd D Dc Novel
PROM1 NM_006017.2 Het IVS
13
c.1579-1G>C r.(spl?) + Highly - - - Novel
CIC04965 Ad CRX NM_000554.4 Het 4 c.608_609del p.(S203Ffs*32) + - - - - Novel
CIC3750 simplex CRX NM_000554.4 Het 3 c.121C>T p.(R41W) + Highly Prd D Dc (rs104894672) [70]
CIC06321 simplex + RPGRIP1 NM_020366.3 Ho 14 c.2021C>A p.(P674H) + Highly Prd T Dc Novel
CIC00190 simplex AIPL1 NM_014336.4 Het 5 c.769C>T p.(L257F) + Moderately Prd D Dc Novel
AIPL1 NM_014336.4 Het 5 c.767T>G p.(I256S) + Moderately B D Dc Novel
Lower confidence d
CIC00162 Ar ABCA4 NM_000350.2 Het 31 c.4546_4547del p.(Q1516Afs*38) + - - - - Novel
ABCA4 NM_000350.2 Het 16 c.2463G>A p.(W821*) + - - - - Novel
CIC05987 Ar ABC4A NM_000350.2 Het 22 c.3295T>C p.(S1099P) + Highly Pd D Dc (rs61750119) [88]
ABC4A NM_000350.2 Het 22 c.3322C>T p.(R1108C) Np - - - - [89]
CIC06694 simplex ABC4A NM_000350.2 Het IVS36 c.5196+1G>A r.(spl?) Np - - - - [62]
ABC4A NM_000350.2 Het 22 c.3322C>T p.(R1108C) Np - - - - [87]
CIC02712 simplex + PDE6C NM_006204.3 Het 10 c.1325T>A p.(M442K) Np Moderately Pd D Dc Novel
PDE6C NM_006204.3 Het 10 c.1375C>G p.(Q459E) Weakly B T Dc Novel
CIC00597 simplex GUCY2D NM_000180.3 Het 14 c.2747T>C p.(I916T) + Moderately Prd D Dc [90]
CIC06352 simplex GUCA1A NM_000409.3 Het 3 c.149C>T p.(P50L) Np Moderately B T Dc (rs104893968) [91]
CIC07188 simplex PROM1 NM_006017.2 Het 12 c.1354dup p.(Y452Lfs*13) Np - - - - [71]
Boulanger-Scem
am
a
et
al.O
rphanet
Journalof
Rare
D
iseases
 (2015) 10:85 
Page
6
of
20
Table 1 Summary of 43 patients carrying pathogenic and likely pathogenic mutations in known CCRD genes (Continued)
PROM1 NM_006017.2 Het IVS
12
c.1454+2>C r.(spl?) Np Highly - - - Novel
CIC03241 simplex CRX NM_000554.4 Het 4 c.564dup p.(A189Rfs*47) + - - - - Not clear if same mutation as
in [69]
CIC07569 simplex CRX NM_000554.4 Het IVS 3 c.252+1G>A r.(spl?) Np Highly - - - Novel
Ar: autosomal recessive; Ad: autosomal dominant; Het: heterozygous; Ho: homozygous; Consang.: Consanguinity; Coseg.: Cosegregation; Np: Not possible; B: Benign; T: Tolerated; Prd: Proabably damaging, Pd: Possible
disease causing; D: Damaging; Dc: Dicease causing
a personal communication B. Puech
b Sergouniotis P. (2012). Genotype and phenotypic heterogeneity in autosomal recessive retinal disease. Ph.D.Thesis. Institute of Ophthalmology, University College London, United Kingdom
c sibling patients. Only one of the 2 siblings (CIC06642) was considered for the mutation prevalence analysis
d these mutations were considered pathogenic with lower confidence because biallelism could not be demonstrated by cosegregation analysis
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These variants were identified in 42 patients (21 spor-
adic cases, 11 ar and 10 ad cases). Interestingly for 2
patients initially considered as sporadic cases, NGS
data led to the identification of heterozygous muta-
tions in genes implicated in ad CCRD. Further clinical
investigation of the patients’ family members revealed
that these patients had finally dominant inheritance
(CIC06757, PRPH2 het c.514C>T p.(R172W) and
CIC05563, SEMA4A het c.302T>C p.(Ile101Thr))
(Additional file 2).
Among the 21 resolved cases other initially classified
sporadic, 5 (23.8 %) harboured heterozygous mutations
in genes implicated in ad forms and 16 (76.2 %) har-
boured homozygous or compound heterozygous muta-
tions in genes implicated in ar cases. We suspected “de
novo” mutations for all 5 sporadic patients with hetero-
zygous mutations in ad genes. For patient CIC03241,
both parents were not clinically affected and did not
carry the pathogenic mutation previously reported in
Leber Congenital Amaurosis (LCA) (CRX het c.564dup
p.(A189Rfs*47) (Additional file 2)). Similarly, for CIC03750,
both parents were unaffected and did not carry the known
pathogenic mutation (CRX het c.121C>T, p.(R41W))
(Additional file 2). Unfortunately, we could not perform
haplotype analysis around these mutations in the respective
families in order to formally exclude non-paternity, in the
absence of ethical agreement for such research. For another
subject, CIC00597 carrying the known pathogenic variant
in GUCY2D c.2747T>C, p.(I916T), only the unaffected
mother and sister who did not carry the change, were avail-
able for genetic analysis (Additional file 2). Patient had lost
contact with his father during childhood and no ophthalmic
status for him was available to us. For two additional spor-
adic cases (CIC06352 carrying the known pathogenic vari-
ant c.149C>T, p.(P50L) in GUCA1A and CIC07569
carrying a novel splice site variant in CRX c.252 + 1G>A)
no other family members were available to further validate
the “de novo” character of the mutation.
Pathogenic mutations in retinal disease genes not
classically associated with CCRD. Table 2 shows
pathogenic or likely pathogenic mutations in other
IRD genes found in 17 patients (4 sporadic cases, 11
ar and 2 ad cases). A total of 19 known and novel
mutations were identified in 12 genes not classically
associated with CCRD. These mutations were previ-
ously reported in RP and LCA (C2Orf71 [35, 36],
MERTK [37], RLBP1 [38], EYS [23, 39], NMNAT1
[40–42], RDH12 [43, 44]), RP1 [45], CRB1 [46, 47]
and TULP1 [48]), Senior-Loken (IQCB1) [49], ad
vitreoretinochoroidopathy (BEST1) [50] and adRP
(ROM1) [51]. Although, TULP1 is not a gene that
was frequently associated with CCRD (not classified
as such in https://sph.uth.edu/retnet/), a recent articlerevealed TULP1 mutation as a novel cause of cone
dysfunction [52].
We re-assessed pathogenic prediction for the pub-
lished and novel variants we identified herein and all of
them remain convincing except one on EYS (p.N745S)
[23, 39], which now appears not conserved with a poor
pathogenic prediction profile (Table 2), most likely due
to novel sequenced species showing also the S amino
acid at position 745.
Mutations in ROM1 and the implication in retinal dis-
orders are a matter of discussion [51, 53, 54] and larger
pedigrees are necessary to validate the pathogenicity of a
variant. Therefore, we classified the ROM1 mutation
identified herein with “Lower confidence” (Table 2).
In addition, we identified two patients with variations
in FSCN2: CIC05379 and CIC05379 carried a heterozy-
gous missense variant c.574C>T, p.(R192C) and a het-
erozygous partial deletion of exon 1 confirmed by qPCR,
respectively (Table 2). For these 2 individuals, we could
not confirm segregation of the variant with a disease
phenotype in the family (informative family members
were not available for genetic testing) and, in view of the
low evidence of the role of this gene in the literature, we
considered these 2 variants not pathogenic [34, 55, 56].
Mutation spectrum in patients with ar cases (Tables 1
and 2, Fig. 2) Taking all gene defects into account,
among the 42 patients (27 patients with mutations in
known CCRD gene defects and 15 patients with gene
defects never associated with CCRD) with 2 or more
pathogenic alleles (22 ar cases and 20 sporadic cases),
mutations in ABCA4 were the most prevalent for ar
cases (15/42 patients, 35.7 %). For the other 12 cases,
mutations were identified in PROM1 (4/42 patients,
9.5 %), PDE6C (3/42 patients, 7.1 %), SEMA4A (1/42 pa-
tients, 2.4 %), CDHR1 (1/42 patients, 2.4 %), CERKL (1/
42 patients, 2.4 %), AIPL1 (1/42 patients, 2.4 %),
RPGRIP1 (1/42 patients, 2.4 %). For the 15 remaining
patients, mutations were identified in genes not classic-
ally associated with CCRD (see below). In addition, for 6
patients, only one pathogenic or possibly pathogenic al-
lele was identified implicating ABCA4 (Additional file 3).
Heterozygous status of these variants was confirmed by
Sanger sequencing. No second mutation was found by
Sanger sequencing poorly covered regions and no evi-
dence of deletion was suspected looking at the coverage
data. MLPA did not identify large deletions for these
cases. In addition, a single published nonsense variant
was identified in IMPG2 at a heterozygous state in one
sporadic case (CIC00680, c.379G>A p.(R127*)) [16] and
another novel single variant also heterozygous was found
in CDHR1 (CIC07507, c.1863dupC p.(I622H*fs54)) in an
ar case with consanguineous parents (Additional file 3).
Sanger sequencing confirmed these two variants. Exonic
regions of these 2 genes were well covered with no
Table 2 Summary of 19 patients carrying pathogenic or likely pathogenic mutations in other retinal disease genes
ID Type Consang. Gene NM Allele
State
Exon cDNA Protein Coseg. Conservation Polyphen2 Sift Mutation
Taster
References
High
confidence
CIC01571 Ar C2Orf71 NM_001029883.2 Ho 1 c.2950C>T p.(R984*) + - - - - [36] (RP)
CIC00643 Ar + C2Orf71 NM_001029883.2 Ho 1 c.1949G>A p.(W650*) Np - - - - Novel (rs371289954)
CIC03112 Ar + MERTK NM_006343.2 Ho 17 c.2214del p.(C738Wfs*32) Np - - - - [37] (RP)
CIC01242 Ar MERTK NM_006343.2 Ho 3_19 c.483-?_c.3000
+?del
- + - - - - Novel
CIC06514 Ar + RLBP1 NM_000326.4 Ho 7_9 c.526-?_c.954
+?del
- Np - - - - Novel
CIC03953 simplex EYS NM_001292009.1 Het 11 c.1673G>A p.(W558*) + - - - - [23] (RP) (rs201823777)
EYS NM_001292009.1 Het 14 c.2234A>G p.(N745S) + Not B - Poly [23] (RP) (rs201652272)
CIC05012 simplex NMNAT1 NM_022787.3 Het 5 c.619C>T p.(R207W) Np Weakly B D Dc [41] (LCA) (rs142968179)
NMNAT1 NM_022787.3 Het 5 c.769G>A p.(E257K) Np Moderately B T Dc [42] (LCA) (rs150726175)
CIC06499 simplex NMNAT1 NM_022787.3 Het 5 c.619C>T p.(R207W) + Weakly B D Dc [41] (LCA) (rs142968179)
NMNAT1 NM_022787.3 Het 5 c.769G>A p.(E257K) + Moderately B T Dc [42] (LCA) (rs150726175)
CIC05394 Ar + RDH12 NM_152443.2 Ho 8 c.806_810del p.(A269Gfs*2) Np - - - - [43] (LCA) (rs386834261)
CIC07241 Ar + RDH12 NM_152443.2 Ho 7 c.464C>T p.(T155I) Np Highly Pr D Dc [44] (LCA) (rs121434337)
CIC07447 Ar RDH12 NM_152443.2 Het 8 c.806_810del p.(A269Gfs*2) + - - - [43] (LCA) (rs386834261)
RDH12 NM_152443.2 Het 8 c.403A>G p.(K135E) + Highly Prd T Dc Novel
CIC00953 simplex IQCB1 NM_001023570.2 Het 6 c.424_425del p.(F142Pfs*5) + - - - - [49] (Senior-Loken/LCA)
IQCB1 NM_001023570.2 Het 8 c.686del p.(T229Mfs*8) + - - - - Novel
CIC01300 Ar + RP1 NM_006269.1 Ho 4 c.1719_1723del p.(S574Cfs*7) Np - - - - [45] (arRP)
CIC05272 Ad BEST1 NM_001139443.1 Het 4 c.76G>A p.(V26M) + Highly Prd D Dc [50] (ADVIRC) (rs121918289)
CIC01380 Ar + CRB1 NM_201253.2 Ho 11 c.3994T>G p.(C1332G) + Highly Prd D Dc Novel (LCA)
CIC00963 Ar + TULP1 NM_003322.4 Ho 11 c.1087G>A p.(G363R) + Highly Pd D Dc Novel (LCA and arRP)
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Table 2 Summary of 19 patients carrying pathogenic or likely pathogenic mutations in other retinal disease genes (Continued)
Lower
confidence
CIC05007 Ad ROM1 NM_000327.3 Het 1 c.339del p.(L114Sfs*8) + - - - - Novel (adRP)
Most likely not
pathogenic
CIC05379 simplex FSCN2 NM_001077182.2 Het 1 c.574C>T p.(R192C) + Highly Prd D Dc Novel (adRP and adMD but
questionable) (rs377025075)
CIC05604 simplex FSCN2 NM_001077182.2 Het 1 Partial deletion - Np - - - - Novel (adRP and adMD but
questionable)
RP: Retinitis Pigmentosa; MD: macular dystrophy; LCA: Leber Congenital Amaurosis; ADVIRC: Autosomal Dominant Vitreoretinochoroidopathy; Ad:autosomal dominant; Ar: autosomal recessive; Consang.: Consangunity;
Coseg.: Cosegregation; Np: Not possible; Poly: Polymorphism ; Het: heterozygous; Ho: homozygous; B: Benign; T: Tolerated; Prd: Proabably damaging, Pd: Possible disease causing; D: Damaging; Dc: Disease causing
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Fig. 2 Gene defect spectrum involved in cone and cone-rod dystrophies. Gene defect prevalence in resolved patients with autosomal recessive
inheritance (N = 42 patients including 20 sporadic cases) and autosomal dominant inheritance (N = 17 patients including 5 sporadic cases). * EYS
disease association with CCRD should be taken with caution. ** the implication of ROM1 in IRD remains to be elucidated in the future. *** after
clinical reassessment, patient’s phenotype was retrospectively more compatible with ADVIRC diagnosis and not CCRD
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lysis. Therefore we concluded that these latter 8
cases with heterozygous variants were not yet solved
(Additional file 3).
Thirty one index cases with parental consanguinity
were included in the study. Among them, 20 were found
to carry homozygous mutations, one was compound het-
erozygous (CIC02712, Table 1), one was carrying a single
variant in ABCA4 (CIC05758, Additional file 3) and an-
other one a single variant in CDHR1 (CIC07507,
Additional file 3) whereas 8 cases did not show any pu-
tative pathogenic variant.
Mutation spectrum in ad cases (Tables 1 and 2, Fig. 2)
Taking all gene defects into account, among the 17
patients with 1 pathogenic or likely pathogenic allele in
genes involved in ad retinal dystrophy (12 ad and 5 spor-
adic cases), GUCY2D (5/17 patients, 29.4 %), CRX (4/17
patients, 23.5 %), PROM1 (2/17 patients, 11.8 %) and
PRPH2 (2/17 patients, 11.8 %) were the most prevalent.
The others genes SEMA4A, GUCA1A were implicated
in 5.9 % (1/17 patients) of cases each. For the remaining
2 patients, mutations were identified in genes not clas-
sically associated with CCRD (Table 2: BEST1 c.76G>A,
p.(V26M) and ROM1 c.339del, p.(L114Sfs*8)). Results of
co-segregation analysis are shown in Additional file 2.
Patients with no variant and coverage analysis For the
unsolved probands, we performed coverage analysis and
Sanger sequencing of poorly covered regions for genes
implicated in CCRD (coverage < 25-fold per base). In
doing so, we did not detect any additional pathogenicmutations. However, for 2 patients (CIC06514 and
CIC01242 included in Table 2) coverage was found null
whatever the depth in regions not classically low-covered by
the NGS in the whole cohort. We suspected homozygous
deletions of these “not-covered regions”, that were second-
ary confirmed by the absence of PCR-amplification and the
CNVs analysis (see below). CIC06514 showed a homozy-
gous 7.36 kb deletion encompassing the last 3 exons (exons
7 through 9) of RLBP1 (Table 2). This deletion was previ-
ously reported in Retinitis Punctata Albescens (RPA) pa-
tients from Morocco [38, 57]. CIC01242 revealed a novel
large homozygous deletion ofMERTK (exons 3 through last
exon 19) (Table 2).
Copy Number Variations (CNVs) analysis was also
performed to detect large deletion or duplication not de-
tected by NGS technique. By this approach, we con-
firmed the 2 homozygous deletions previously detected
by coverage analysis in RLBP1 and MERTK. We also de-
tected 1 additional novel heterozygous exon 1 deletion
of PRPH2 (CIC03621), which was confirmed by MLPA
(Table 1). In addition, while performing MLPA on patients
with one single variant on ABCA4, we also performed
ABCA4-MPLA on patients with no known variant and
inheritance compatible with ar mode of inheritance. No
additional deletion on ABCA4 was identified applying this
technique.
To summarize, in a total of 95 unrelated index
patients, targeted NGS identified pathogenic variants
in 59 (62.1 %) cases. In addition, in 8 more sporadic
cases (8.4 %), only one pathogenic variant in ABCA4
Boulanger-Scemama et al. Orphanet Journal of Rare Diseases  (2015) 10:85 Page 12 of 20(6/8) or IMPG2 (1/8) or CDHR1 (1/8) was found.
Providing that these later cases are not solved, our
targeted NGS approach identified in 42 of 78 sporadic
and ar (53.8 %) and in 17 of 17 ad (100 %) cases dis-
ease causing mutations. Of notes coverage and CNV
analysis of NGS raw data was useful to resolve cases
with large deletions, for which the first step of NGS
analysis did not identify disease causing variants.
Phenotype and clinical reassessment of patients with
mutations in IRD genes not classically associated with CCRD
Medical charts from patients with mutations in genes
not classically associated with CCRD were reviewed in
order to reassess clinical diagnosis.
CIC01571 and CIC00643 carried homozygous non-
sense mutations in C2Orf71, among which, one was
novel and one was previously reported in RP [36]. For
both patients, CRD diagnosis was confirmed according
to disease history with primary photophobia and central
vision loss associated with predominant central involve-
ment in autofluorescence imaging (Fig. 3). ERG was not
useful for differential diagnosis in these cases since re-
sponses were undetectable for both scotopic and pho-
topic conditions.
CIC06514 carried a homozygous deletion in RLBP1
previously described in Moroccan patients with Retinitis
Punctata Albescens (RPA) [38, 57]. Our patient was
from Algeria, with one sister and one brother affected
with RP. He presented high myopia, bilateral keratoco-
nus and surgically removed bilateral congenital cataract.
Phenotype was severe with vision reduced to hand mo-
tion in both eyes. ERG responses were undetectable for
both scotopic and photopic conditions. Fundoscopy
showed retinal vessel narrowing, optic disc pallor, per-
ipheral pigment deposits and extensive chorioretinal at-
rophy. No tiny white dots were observed around the
fovea and beyond the vascular arcades as expected in
RPA. Phenotype was consistent with both CRD and RP,
without any possibility of distinction between the 2 diag-
noses at this late stage of the disease. However, accord-
ing to Dessalces and co-workers, the presence of the
white dot-like deposits could be an inconstant finding in
RPA, in particular in children or in patients with late-
stage disease [57]. Fundus examination of this patient at
an earlier stage of the disease would have been useful to
formally exclude RPA.
CIC03953 carried compound heterozygous changes in
EYS already associated with RP patients [23, 39]. Her fun-
dus showed optic disc pallor, retinal vessel narrowing and
pigmentary changes in macular region. ERG revealed un-
usual features: under scotopic conditions, there was no de-
tectable b-wave in response to a dim (0.01 cd.s.m−2) flash
while responses to a bright flash showed some reduction of
the a-wave but additional b-wave reduction leading to anelectronegative waveform. Photopic responses were se-
verely affected in keeping with cone-rod dysfunction with
most likely additional inner retinal dysfunction. The SD-
OCT revealed a preserved outer nuclear layer thickness
but a disruption of the inner segment ellipsoid and inter-
digitation zones in the foveal region. According to the ERG
and SD-OCT findings, atypical CRD diagnosis was retained
rather than RP diagnosis (Fig. 4). As above mentioned, al-
though one of the variant carried by this patient is a
pathogenic nonsense variant (c.1673G>A p.(W558*)), the
second variant is a misssense (c.2234A>G p.(N745S)) with
now a questionable pathogenicity. Therefore, although
CIC03953 revealed a very peculiar phenotype considering
CRD, disease association with EYS should be cautious.
CIC05012 and CIC06499 carried compound heterozygous
mutations (c.619C>T p.(R207W) + c.769G>A p.(E257K)) in
NMNAT1, which was recently reported to be responsible
for LCA associated with macular coloboma-like atro-
phic lesions [40–42, 58]. The first patient (CIC05012)
was 8 years old and presented sporadic central visual
loss since early childhood without nystagmus. ERG
showed primarily cone dysfunction consistent with CRD.
Fundoscopy revealed bilateral and asymmetrical sharply
demarcated macular atrophic lesions, which could be
considered as pseudocoloboma. The second patient
(CIC06499) had also poor vision since infancy with pre-
dominantly cone dysfunction in ERG. Fundus examin-
ation showed macular atrophic changes with widespread
loss of autofluorescence at the posterior pole but no
macular coloboma-like lesion.
CIC00953 was found to be compound heterozygous
for two small deletions in IQCB1 including one already
reported in Senior-Loken syndrome [49] and one novel.
Mutations in this gene have also been associated with
LCA with a need for monitory kidney function due to
the variable age of onset of the nephronoptis associated
with this gene. Our patient did not have renal insuffi-
ciency and displayed more a CCRD phenotype with
photophobia, vision reduced to 20/32 in the right eye
and 20/100 in the left eye at age 28, central scotoma,
cone-rod dysfunction on ERG and moderate autofluo-
rescence changes. Based on this new genetic finding,
the patient was advised to regularly monitor her kid-
ney function.
CIC05272 carried a missense mutation in BEST1
(c.76G>A p.(V26M)) already associated with Autosomal
Dominant Vitreoretinochoridopathy (ADVIRC) [50]. Pa-
tient’s phenotype was retrospectively more compatible
with ADVIRC diagnosis with vitreous fibrillar condensa-
tion, circumferential hyperpigmented band in peripheral
retina and severely abnormal responses on electrooculo-
gram. Microphtalmos and congenital cataract were ob-
served in other family members, which is consistent
with ADVIRC.
Fig. 3 Phenotype of CIC01571 who carries a homozygous nonsense mutation in C2Orf71, previously reported in RP. (a) Pedigree of family 1932.
History of symptoms reveals initial photophobia and bilateral central vision loss. Visual acuity is reduced to hand motion in both eyes. Colour
fundus photographs (b), infra-red (c) and blue autofluorescence imaging (d) confirm the predominant central involvement with severe bilateral
macular atrophy. SD-OCT (e) shows the disappearance of the photoreceptor layers that extends beyond the vascular arcades. ERG responses
(not shown) were undetectable from background noise in both scotopic and photopic conditions
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zygous missense mutation in CRB1, gene known to be
implicated in LCA and RP [47]. Clinical presentation
was consistent with CRD. Fundus examination showed
bilateral and symmetric bull’s eye maculopathy. Autoflu-
orescence imaging revealed bilateral macular atrophy
and ERG showed predominant cone dysfunction. No
typical CRB1 phenotypic features as hypermetropic
refractive error, nummular pigmentation at the level ofthe RPE or increased retinal thickness on OCT were
found in this patient [59].
For CIC05007 carrying a mutation in ROM1, clinical
reassessment confirmed the diagnosis of CRD with pre-
dominant cone dysfunction in ERG. Fundus examination
revealed optic disc pallor, retinal vessel narrowing and
macular pigmentary changes. Autofluorescence pattern
was atypical with central hypoautofluorescence sur-
rounded by a large hyperautofluorescent ring with
Fig. 4 Phenotype of CIC03953 who carries a compound heterozygous mutation in EYS. (a) Pedigree of family 1819. Visual acuity is 20/50 with −2.50
(−0.25)25° in the right eye and 20/80 with −2.50 (−0.75)170° in the left eye. Kinetic perimetry shows a bilateral central scotoma. Color fundus
photographs (b) show bilateral optic disc pallor, retinal vessels narrowing and macular pigmentary deposits. Infra-red (c), infra-red autofluorescence
(d) and blue autofluorescence imaging (e) highlight macular pigmentary and atrophic changes. SD-OCT (f) reveals a predominant central involvement
with a disruption of the outer retinal layers limited in the fovea. ERG (g) revealed unusual features in association for EYS mutations: under
scotopic conditions, there was no detectable b-wave in response to a dim (0.01 cd.s.m−2) flash while responses to a bright flash showed
some reduction of the a-wave but additional b-wave reduction leading to an electronegative waveform. Photopic responses were severely
affected in keeping with cone-rod dysfunction with additional inner retinal dysfunction
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of ROM1 in IRD remains to be elucidated in the future.
The 7 remaining patients carried mutations in MERTK
(CIC03112, CIC01242), RP1 (CIC01300), RDH12 (CIC05394,
CIC07241, CIC07447), TULP1 (CIC00963), which were
known to be associated with RP or LCA. For these pa-
tients, ERG responses were undetectable in both scotopic
and photopic conditions. Distinction between RP and
CRD could not be made in the absence retrospective data.
Discussion
Using NGS approach targeting exons of 123 genes
known to be implicated IRDs in a total of 95 unrelated
index patients, we could identify likely pathogenic vari-
ants in 59 (62.1 %) cases, including those with high and
lower confidence. Being more stringent excluding the
cases for whom no family members were available to
demonstrate biallelism, we would obtain a detection rateof 52 % (49/95). In addition, in 8 more sporadic cases
(8.4 %) only one pathogenic variant was found including
6 in ABCA4. Of notes coverage and CNV analysis of
NGS raw data was useful to resolve cases with large de-
letions, for which the first step of NGS analysis did not
identify disease causing variants. Providing that ar cases
with only one variant are not solved, our targeted NGS
approach identified in 42 of 78 sporadic and ar (53.8 %)
and in 17 of 17 ad (100 %) cases disease causing muta-
tions. This mutation detection rate difference between ar
and ad cases may be explained by the fact that our panel
targets all genes involved in adCCRD identified so far
but is less comprehensive for arCCRD-associated genes
(i.e. at least 3 novel genes were not included RAB28,
C21Orf2 and TTLL5). It also reinforces the genetic het-
erogeneity of arCCRD and may also suggest additional
gene defects to be discovered in this genetic group
which may not be the case for adCCRD.
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known IRD genes applied to CCRD patients. In a recent
study, Huang et al used a similar approach including 25
associated-CRD genes to investigate 47 CRD Chinese
families [21]. All patients had previously been excluded
for mutations in major known genes (CRX, GUCY2D,
GUCA1A, PRPH2, KCNV2) and for reported mutations
in 17 other CRD genes [60]. Their mutation detection
rate was 21 % (10/47 families), with 14 potential patho-
genic mutations identified, of which 9 were novel. The
current study provides a more comprehensive tool, since
it screens 123 genes implicated in various IRDs with dif-
ferent inheritance patterns. The detection mutation rate
is relatively high (62.1 %) and similar to those obtained
for RP [19]. Applying NGS to our retinal disease panel,
33 known and 35 novel mutations were detected in
different patients.
Identification of these mutations reaffirms the clinical
and genetic heterogeneity of CCRD, and further expands
the mutation spectrum of CCRD. Overall in this cohort,
the prevalence of known genes was 15.8 % for ABCA4
(15/95 patients), 6.3 % for PROM1 (6/95 patients), 5.3 %
for GUCY2D (5/95 patients), 4.2 % for CRX (4/95 pa-
tients), 3.2 % for PDE6C (3/95 patients), 2.1 % each for
SEMA4A and PRPH2 (2/95 patients each), 1 % each for
CDHR1, CERKL, GUCA1A, RPGRIP1, AIPL1 (1/95 pa-
tients each). These results confirm that mutations in
ABCA4 are the most prevalent gene defect implicated in
CCRD. Not counting patients with suspected or con-
firmed ad transmission (17 patients), pathogenic or likely
pathogenic ABCA4 mutations were found in 15/78 ar
and sporadic CCRD patients (19.2 %). In addition, 6
patients carried at least 1 ABCA4 mutation (7.7 %). This
rate is similar to those described in the literature. Using
direct sequencing techniques, Maugeri et al found muta-
tions in both ABCA4 alleles in 6/20 ar/simplex cases
(30 %) [9]. In a study including 54 ar or simplex CRD
patients, Klevering et al found homozygous or com-
pound heterozygous mutations in ABCA4 in 9 patients
(16 %) [61]. Kitiratschky and colleagues identified
ABCA4 mutations on both alleles in 25 % of cases (16/
64 patients with arCCRD) [62]. Most of these previous
studies included smaller cohorts so that ABCA4 preva-
lence could have been over estimated. Similarly to previ-
ous studies, a significant proportion of patients carried
only one pathogenic allele. MPLA did not reveal any
large deletions or genomic rearrangement mutations in
these patients in keeping with the literature [63, 64].
Braun and co-workers were first to provide evidence for
the possibility of intronic variants near rare alternate
splice junctions that could be pathogenic by increasing
the probability of mis-splicing at these sites [65]. Deep
intronic mutations leading to truncated proteins have
also been described in Usher syndrome and LCA [66,67]. This need to be further investigated in our 6
patients. Another hypothesis is that single heterozygous
variants found in ABCA4 are not causative in these
cases. The same reasoning holds true for the patients
carrying a single pathogenic allele in IMPG2 or CDHR1.
Indeed, the presence of additional pathologic mutations
in genes different from the causative gene in IRD
patients is a frequent event that has been highlighted
by high throughput sequencing. Implication of these
variants in pathogenicity is unknown. Some genes
could play a modifying role on the expression or not
of the disease. Only functional studies could help to
better understand these potential interactions.
As previously reported, mutations in GUCY2D are
the major gene defect implicated in ad CCRD, which
was found in 5/17 ad CCRD patients (29.4 %) in this
study [11]. Sanger sequencing of German families
with 10 ad CCRD found similar results with GUCY2D
mutations in 25 % of cases [68]. In the same study,
prevalence of CRX and PROM1 were low (4 % and
2 % respectively) compared with our results (2/17 for
PROM1, 4/17 for CRX, 11.7 % and 23.5 %,
respectively).
Furthermore, inheritance pattern could be better de-
fined for 25 sporadic cases (2 of the 27 initial sporadic
cases revealed ad transmission after clinical investigation
of the family members), who were predominantly ar (20/
25 patients, 80 %). The remaining 5 patients showed
mutations in ad genes (CIC03241, CIC03750 and
CIC07569 in CRX, CIC00597 in GUCY2D, CIC06352 in
GUCA1A of which 2 were novel). Regions carrying the 3
CRX mutations were repetitive and were therefore likely
to be the site of neomutations. The “de novo” nature of
all these mutations could only be confirmed for 2 pa-
tients whose parents did not carry the pathogenic muta-
tion (c.564dup p.(A189Rfs*47) and c.121C>T p.(R41W)
in CRX previously reported in LCA [69, 70]. We actually
could not perform haplotype analysis around these mu-
tations for these families in order to formally exclude
non-paternity, in the absence of ethical agreement for
this research. In the 3 other cases, we did not manage to
genetically investigate their parents (DNA was only
available in 1 out of 2 parents for 1 patient and not
available for the others) and clinically, in order to con-
clude. These results should be taken into consideration
for patient management since it could modify genetic
counselling. Further studies are needed to better esti-
mate the prevalence of pathogenic neomutations in
inherited retinal disorders.
This approach can revisit mode of inheritance of gene
defects in CCRD and identify new phenotype-genotype
associations. As previously reported, mutations in
PROM1 are known to be associated with both recessive
and dominant inheritance. According to Pras et al,
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hort) result in a mutant protein that exerts a dominant
negative effect explaining the ad inheritance. In contrast,
severe frameshift mutations (c.1354dup p.(Y452Lfs*13);
c.7dup p.(L3P*28)) most likely abolish the function of
one allele with the other functioning allele being suffi-
cient to maintain normal retinal activity. Symptoms de-
velop only when both alleles are not expressed [71].
Similarly, mutations in AIPL1 are already known to be
implicated in both ar LCA and ad CRD [72]. A recent
study identified two homozygous mutations in AIPL1
(c.773G>C (p.R258P) and c.465G>T (p.(H93_Q155del)) in
two Pakistani families, which co-segregated with disease
phenotype that could correspond to ar LCA or ar RP [73].
In 1 patient of our cohort, 2 novel likely pathogenic muta-
tions were identified in exon 5 of AIPL1 (het c.769C>T
p.(L257F) + het c.767T>G p.(I256S)), one carried by the
unaffected father and one by the unaffected mother. This
would suggest that AIPL1 mutations can also lead to ar
CRD although no additional affected member was avail-
able to confirm pathogenicity. Lastly, one patient with
severe simplex CRD carried a novel homozygous non-
sense mutation in SEMA4A (c.241C>T p.(R81*)), known
to be responsible for ad CRD or ad RP. Although no other
family members were available for co-segregation analysis,
this truncating mutation is likely causative and would also
expand the spectrum of SEMA4A to CRD with ar inherit-
ance. SEMA4A mutations previously described in ad RP
or ad CRD were missense mutations localized between
codon number 345 and 713 [74]. In our case, the mutation
was homozygous, nonsense and localized earlier on the
protein (codon number 81). We hypothesized that in ad
cases, mutations of one allele lead to abnormal product
that exerts a dominant negative effect on the normal
product from the non mutated allele. On the opposite, in
ar cases, mutations are more severe (nonsense, earlier on
the genomic sequence) with product degradation due to
nonsense-mediated RNA decay, leading to haploinsuffi-
ciency. In the last cases, mutations in both alleles are ne-
cessary to develop the disease. However, this hypothesis
needs to be confirmed by further functional analysis.
Another hypothesis is that the mutation p.(R81*) at the
heterozygous state is enough to be pathogenic. However,
one must be cautious before concluding on this first ar
mutation in SEMA4A, since cosegregation analysis was
not possible to document the biallelism in association with
the disease.
This approach also allowed us to establish new
genotype-phenotype correlations or to refine clinical diag-
nosis. In this cohort, 17 patients showed inconsistency be-
tween molecular diagnosis and initial clinical diagnosis.
Clinical reassessment was performed to resolve these
cases. For one patient, clinical diagnosis was modified
based on additional clinical data (CIC05272: ADVIRC).For another patient, (CIC00953: IQCB1) genetic analysis
led to monitoring of renal function with a significant
consequence on patient management. For 7/17 patients,
CRD diagnosis was confirmed, suggesting new genotype-
phenotype correlations for the following genes.C2Orf71 CRD diagnosis was confirmed for both
CIC00643 and CIC01571, suggesting that C2Orf71 is not
only responsible for RP (≈1 % of cases according to
Audo et al [36]) but also for CRD, with an estimated
prevalence of 2.5 % in this cohort (2/78 ar or sporadic
patients). This is in accordance with findings by Collin
et al who previously reported two patients with ERG
recordings suggesting more affected cone than rod func-
tion, although both photoreceptor functions were
severely damaged [35].EYS Diagnosis of atypical CRD was retained for
CIC03953. A recent report described the case of a
Japanese patient with ar CRD and compound hetero-
zygous truncating mutations in EYS [75]. With our
additional case, we confirmed that the phenotypic
spectrum of EYS mutations can be extended to ar
CRD, but we also described a new EYS-related
phenotype, characterized by a scotopic electronegative
waveform in ERG. However, as mentioned before, the
pathogenic character of the missense mutation in this
patient needs to be confirmed.NMNAT1 Although clinical presentations of 2 patients
(particularly CIC05012) were not highly suggestive of
NMNAT1-mutant phenotype, Chiang and colleagues
have already reported in their cohort 1 patient with con-
firmed CRD diagnosis who carried a compound hetero-
zygous mutation in NMNAT1, including the most
frequent variant c.769G>A p.(E257K) [42]. According to
these observations, the clinical spectrum of NMNAT1
could be expanded from LCA to CRD. However, these
findings are not consistent with a recent report that did
not identify disease-causing NMNAT1 mutations among
108 CRD patients [76]. Furthermore, the interpretation
of the most frequent variant (c.769G>A p.(E257K))
should be interpreted with caution since it was recently
found homozygous in a subject with no ocular abnor-
malities, suggesting that this variant may not be fully
penetrant [77]. Siemiatkowska et al hypothesized that
this hypomorphic variant causes LCA in combination
with a more severe NMNAT1 variant. Incomplete pene-
trance may be due to trans- or cis-acting elements,
which could influence its expression. Another hypothesis
is that this variant is not pathogenic but rather is in link-
age disequilibrium with an undetected mutation.
Boulanger-Scemama et al. Orphanet Journal of Rare Diseases  (2015) 10:85 Page 17 of 20CRB1 Although CIC01380 did not show common
phenotypic features associated with CRB1, Henderson et
al reported a high clinical variability in IRDs due to
CRB1 mutations [59]. Furthermore, as in our patient,
they observed macular atrophy in 29 % of cases in a
cohort of 34 CRB1-associated RP and LCA. In the same
cohort, 3 patients showed more a CRD phenotype than
RP with early onset decreased vision, generalized photo-
receptor dysfunction and evidence of more severe macu-
lar dysfunction. No macular atrophy was reported in
these 3 cases. According to these findings, CRD should
be considered part of the clinical spectrum associated
with CRB1 mutation.
TULP1 We did not consider this gene as known to be
associated with CCRD since it was not listed in Retnet
database. However, using a homozygosity mapping
approach in a cohort of 159 CCRD, Roosing et al. [52]
recently reported the cases of 2 unrelated patients with
predominantly cone-mediated phenotype (1 with CD
and 1 with CRD) carrying a novel homozygous missense
mutation (p.R420S) in TULP1, predicted as pathogenic.
Both patients were sporadic cases from consanguineous
parents with heterozygous status for the mutation so no
cosegregation analysis with the disease could be per-
formed [52]. Our additional case confirms that the disease
spectrum of TULP1 mutations extends from early-onset
RP to cone-dominated disease. Further research is
required to elucidate the molecular mechanisms associ-
ated with the different diseases associated with TULP1
mutations and will aid a better understanding of the func-
tion of TULP1 in cones and rods.
ROM1 CIC05007 and his affected sibling carried a novel
heterozygous frameshift deletion in ROM1 (c.339del
p.(L114Sfs*8)). This gene was initially reported in digenic
RP with PRPH2 mutation [78] and then implicated in a
family with monogenic RP (c.339dupG p.(L114Afs*18))
[79]. However pathogenicity of mutations in ROM1 is
still a matter of debate. In a recent study, Jinda and col-
leagues found the known heterozygous ROM1 variant
p.(L114Afs*18) in 2/240 normal controls, and in 1 ar RP
with likely causative mutation already detected in
C8Orf37. In our patient, the selected ROM1 mutation is
considered to be causative with low confidence. Further
co-segregation analysis could document the association
between CRD and the genetic defect.
By using targeted NGS, 36 patients (37.9 %) were still
genetically unresolved and could be further investigated
with whole exome sequencing (WES). In our experience,
coverage analysis of genes of interest by direct sequen-
cing of low-covered regions should be systematically
performed, particularly in regions with null coverage
whatever the depth. This step is essential before WES, inorder to exclude rare mutations in low-covered regions
and more importantly, homozygous exonic deletions as
found in this study.
Conclusions
In summary, in this study, we applied NGS to a cohort
of 96 CCRD patients using a comprehensive panel of
123 IRD genes. Using this approach, prevalence of gene
defects underlying ad CCRD and ar CCRD were de-
termined for the first time in a large cohort. Novel
mutations were found, expanding the mutations
spectrum of CCRD. New genotype-phenotype correla-
tions were identified, confirming that genetic of IRD
is complex with an extensive overlap between CCRD
and other retinal diseases.
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